Module 9: Carcinogenicity
Recorded On: 12/25/2025
This presentation provides a stepwise overview of evaluating potential carcinogenicity in rodents, with a focus on pharmaceuticals. Following a brief history of chemical carcinogenicity, the presentation outlines possible study objectives, recommendations for carcinogenicity studies set by regulatory agencies, and key factors in designing a strategy to evaluate and predict carcinogenicity. The presentation covers specific topics related to planning a carcinogenicity study, study design, internal and regulatory review of carcinogenicity study protocols, and study oversight and interpretation. The presentation also discusses weight-of-the-evidence approaches for both small molecules and biologics. The presentation concludes by addressing the interpretation of “positive” results for assessing human safety, the regulatory implications of a “positive” study, and provides examples of how positive carcinogenicity study findings are addressed in product labeling.
Timothy McGovern, PhD
Principal Consultant
White Oak Regulatory Tox, LLC
Dr. Timothy McGovern is a co-founder and Principal Consultant of White Oak Regulatory Tox, LLC, where he provides advice to pharmaceutical companies related to all aspects of nonclinical programs intended to support pharmaceutical drug development from first in human clinical trials to marketing applications.
Dr. McGovern recently completed a 22-year career at the US Food and Drug Administration (FDA) where he spent the past 11 years as an Associate Director for Pharmacology and Toxicology in the Office of New Drugs (OND) of the Center for Drug Evaluation and Research (CDER). He served as a member of the Pharmacology/Toxicology Senior Leadership Team within OND and was responsible for the development of policy and guidance related to nonclinical and regulatory issues including FDA and International Council for Harmonization (ICH) guidance initiatives. He was also a standing member of CDER’s Executive Carcinogenicity Assessment Committee as well as CDER’s Genetic Toxicology and Pharmacology/Toxicology Education Subcommittees.
Dr. McGovern was a member of multiple ICH Expert Working Groups including S1B (Testing for Carcinogenicity of Pharmaceuticals), M7 (DNA reactive impurities), Q3C (Residual Solvents), and Q3D (Elemental Impurities), serving as Topic Lead and Rapporteur. Dr. McGovern was also a member of CDER’s Task Force on Nitrosamines in Drug Products providing nonclinical expertise in developing policies, addressing clinical safety issues, and interacting with other Drug Regulatory Agencies and Industry stakeholders. He participated in drafting FDA’s Guidances “Control of Nitrosamine Impurities in Human Drugs” and “Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs)” and served as Chair of the CDER Pharm/Tox Nitrosamines Working Group.
Dr. McGovern earned a doctorate degree in inhalation toxicology from New York University and first joined OND’s Division of Pulmonary and Allergy Products (DPAP) as a primary reviewer. He later supervised review teams in DPAP as well as the Division of Anesthetic and Critical Care Products.